药格局 YaoGeJuCDE public lists · weekly counts
National Drug-Review Weekly
2024/10/01 – 2024/10/07
- New acceptances this week
- 18
- Drugs with new generic filings (by drug name, de-duplicated)
- 2
- Accepted this week, now under review
- 0
DefinitionAcceptance numbers accepted this week that still appear on CDE's under-review list at the data cutoff; counted by acceptance date from the daily full pull of that list, independent of snapshot history.
Drug and company names link to detail pages; sign in to view them.
New acceptances this week
By application type and drug type
18filings, 3 of them generic
By application type
| Application type | Filings |
|---|---|
| Supplement | 11 |
| New drug | 4 |
| Generic | 3 |
By drug type
| Drug type | Filings |
|---|---|
| Chemical drug | 15 |
| TCM | 1 |
| 治疗用生物制品 | 1 |
| 预防用生物制品 | 1 |
DefinitionAcceptance numbers whose acceptance date falls in this week; application type and drug type are the CDE list's own text, with empty values shown as “Unspecified”.
Most new generic filings, by drug
2 drugs with new generic filings; top 10 listed
DefinitionThis week's acceptance numbers with application type “Generic”, grouped by identical drug name; filing companies are de-duplicated by first applicant; under review, all years = acceptance numbers for that name, from any year, still on the CDE under-review list. Top 10 by filings, then companies.
Most new acceptances, by company
12 companies with new acceptances; top 10 listed
| # | Company (first applicant) | Filings | Drugs | Generic |
|---|---|---|---|---|
| 1 | 南京中澳转化医学研究院有限公司 | 3 | 1 | 0 |
| 2 | Janssen-Cilag NV | 2 | 1 | 0 |
| 3 | Roche Pharma (Schweiz) AG | 2 | 1 | 0 |
| 4 | 成都峻禾医药科技开发有限公司 | 2 | 1 | 2 |
| 5 | 西安杨森制药有限公司 | 2 | 1 | 0 |
| 6 | Genzyme Corporation | 1 | 1 | 0 |
| 7 | Novartis Pharma Schweiz AG | 1 | 1 | 0 |
| 8 | 景忠山国药（唐山）有限公司 | 1 | 1 | 0 |
| 9 | 江苏中慧元通生物科技股份有限公司 | 1 | 1 | 0 |
| 10 | 江苏海岸药业有限公司 | 1 | 1 | 0 |
DefinitionThis week's acceptance numbers grouped by first applicant; drugs are de-duplicated by drug name; “Generic” counts filings with application type “Generic”. Top 10 by filings.
Under-review list changes
Compared across this platform's snapshots of the under-review list
Data collected since 2026/10/22. There is not enough snapshot history for this week yet; counts of filings entering and leaving review start with the next complete week.
DefinitionEntered review = acceptance numbers seen for the first time in this platform's under-review snapshots this week, excluding the baseline records of the first snapshot day (2026/10/22). Left review = acceptance numbers whose last snapshot sighting falls in this week and that this snapshot no longer lists; the outcome follows NMPA's approval-document delivery notices, and numbers without such a record are marked to be checked. Companies are counted by first applicant.
Class 3 and new-drug acceptances
6 this week
| Accepted | Drug | Applicants |
|---|---|---|
| 2024/10/01Generic · Class 3 | 盐酸普罗帕酮注射液CYHS2403329 | 成都峻禾医药科技开发有限公司; 四川美大康佳乐药业有限公司 |
| 2024/10/01Generic · Class 3 | 盐酸普罗帕酮注射液CYHS2403328 | 成都峻禾医药科技开发有限公司; 四川美大康佳乐药业有限公司 |
| 2024/10/01New drug · Class 3.2 | 流感病毒亚单位疫苗CXSS2400107 | 江苏中慧元通生物科技股份有限公司 |
| 2024/10/01New drug · Class 1 | CA1257胶囊CXHL2401034 | 南京中澳转化医学研究院有限公司 |
| 2024/10/01New drug · Class 1 | CA1257胶囊CXHL2401033 | 南京中澳转化医学研究院有限公司 |
| 2024/10/01New drug · Class 1 | CA1257胶囊CXHL2401032 | 南京中澳转化医学研究院有限公司 |
DefinitionThis week's acceptance numbers with application type “New drug”, or registration applications whose class starts with 1, 2 or 3 (supplements and re-registrations excluded); newest first, at most 30 rows.
Subscribe to the weekly
No account needed.
The email carries the same content as this page, in the language you subscribe in: section counts, top-10 lists and definitions, with a link to the full report. Your address is used only to send the report.